论文部分内容阅读
目的观察核苷类似物(恩替卡韦)与胸腺五肽联合治疗抗乙肝病毒的效果。方法选取慢性乙型病毒性肝炎67例,恩替卡韦联合胸腺五肽组32例,单用恩替卡韦组35例,用药前、用药1个月、3个月后、6个月后复查HBV DNA。结果用药1个月后两组HBV DNA水平皆有明显下降,但均数无显著性差异,用药3个月后2组HBV DNA水平皆有明显下降,均数有显著性差异。恩替卡韦+胸腺五肽组低于单用恩替卡韦组(P<0.05)。用药6个月后2组HBVDNA水平皆有明显下降,但均数无显著性差异(P>0.05)。用药1个月后,恩替卡韦+胸腺五肽组HBV DNA转阴率21%,单用恩替卡韦组HBV DNA转阴率为7%,有统计学意义。用药3个月后恩替卡韦+胸腺五肽组HBV-DNA转阴率明显高于单用恩替卡韦组(89%vs57%,P<0.05)。用药6个月后恩替卡韦+胸腺五肽组HBV-DNA转阴率高于单用恩替卡韦组(91%vs90%),但统计学上无差异。结论恩替卡韦是一种很好的抗HBV药物,无论单用或与胸腺五肽合用均可使HBV DNA明显下降,但在与胸腺五肽联用后使HBVDNA水平下降更加显著,特别是提高了HBV DNA转阴率,说明核苷类似物恩替卡韦与胸腺五肽联用能使HBV DNA尽早转阴,提高了抗病毒的早期应答率。
Objective To observe the effect of nucleoside analogue (entecavir) combined with thymopentin on anti-hepatitis B virus. Methods Sixty-seven patients with chronic viral hepatitis B, 32 patients with entecavir and thymopentin and 35 patients with entecavir alone were enrolled. HBV DNA was examined 6 months after treatment and 1 month, 3 months and 3 months after treatment. Results After 1 month of treatment, the HBV DNA levels in both groups were significantly decreased, but there was no significant difference. After 3 months of treatment, the levels of HBV DNA in both groups were significantly decreased, with significant differences. Entecavir + thymopentin group was lower than entecavir alone group (P <0.05). After six months of treatment, the two groups of HBVDNA levels were significantly decreased, but no significant difference (P> 0.05). After 1 month of treatment, the HBV DNA negative rate was 21% in entecavir + thymopentin group, and the negative rate of HBV DNA in entecavir group was 7%, which was statistically significant. HBV-DNA negative rate of entecavir + thymopentin group was significantly higher than that of entecavir alone group (89% vs 57%, P <0.05) after 3 months. HBV-DNA negative rate of entecavir + thymopentin group was higher than that of entecavir alone group (91% vs 90%) after 6 months of treatment, but there was no statistical difference. Conclusion Entecavir is a good anti-HBV drug. HBV DNA can be significantly decreased both in combination with thymopentin and HBV DNA in combination with thymopentin. In particular, HBV DNA is increased DNA negative rate, indicating that the nucleoside analogue of entecavir thymopentin combined with HBV DNA can be negative as soon as possible to improve the early response rate of antiviral.